Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms. | Biochem Genet | 2025 | 38722434 | PubTator, text mining | PubMed |
| Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease. | bioRxiv | 2025 | 38260617 | PubTator, text mining | PubMed |
| Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers. | J Oncol Res Ther | 2024 | 40083977 | PubTator, text mining | PubMed |
| Mapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface. | ACS Omega | 2024 | 39676951 | PubTator, text mining | PubMed |
| Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells. | Immunol Res | 2024 | 39661295 | PubTator, text mining | PubMed |
| Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis. | Cancer Med | 2024 | 39659057 | PubTator, text mining | PubMed |
| A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy. | Biomark Res | 2024 | 39617949 | PubTator, text mining | PubMed |
| Identification of VISTA regulators in macrophages mediating cancer cell survival. | Sci Adv | 2024 | 39602545 | PubTator, text mining | PubMed |
| Association Between VISTA and Vascular Cognitive Impairment in Older Chinese Adults: A Cross-Sectional Study. | Clin Interv Aging | 2024 | 39600532 | PubTator, text mining | PubMed |
| Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy. | J Immunother Cancer | 2024 | 39572160 | PubTator, text mining | PubMed |
| The novel immune landscape of immune-checkpoint blockade in EBV-associated malignancies. | FASEB J | 2024 | 39520274 | PubTator, text mining | PubMed |
| Peripheral immune profiling of soft tissue sarcoma: perspectives for disease monitoring. | Front Immunol | 2024 | 39502689 | PubTator, text mining | PubMed |
| VISTA-mediated immune evasion in cancer. | Exp Mol Med | 2024 | 39482534 | PubTator, text mining | PubMed |
| A comprehensive review of immune checkpoint inhibitors for cancer treatment. | Int Immunopharmacol | 2024 | 39447408 | PubTator, text mining | PubMed |
| Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins. | Eur J Med Chem | 2024 | 39437574 | PubTator, text mining | PubMed |
| High-expression of V-domain Imuunoglobulin Suppressor of T-cell Activation (VISTA) Is Correlated with Advanced Pathological Features in Patients with Pancreatic Ductal Adenocarcinoma. | Iran J Allergy Asthma Immunol | 2024 | 39422386 | PubTator, text mining | PubMed |
| TAM-tastic: from resistance to resilience in cancer. | Trends Pharmacol Sci | 2024 | 39358174 | PubTator, text mining | PubMed |
| Small-Molecule Radiotracers for Visualization of V-Domain Immunoglobulin Suppressor of T Cell Activation. | J Med Chem | 2024 | 39305257 | PubTator, text mining | PubMed |
| Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment. | Heliyon | 2024 | 39286218 | PubTator, text mining | PubMed |
| Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss. | Int J Mol Sci | 2024 | 39273326 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=11